Technological Innovation and Social Commitment
ADmit Therapeutics S.L. is a pioneering company in the application of innovative technologies in the field of neurodegenerative diseases, with a strong social component. Its main asset is a highly trained team with experience in medical diagnostics, neurobiology, artificial intelligence, and the development and marketing of medical devices. Its quality is demonstrated by the clearance of the manufacturing license from the Spanish Agency of Medicines and Medical Devices (AEMPS), the ISO 13485 certification, and the laboratory accreditation from the College of American Pathologists (CAP), becoming the first Spanish laboratory to achieve this recognition.
The MAP-AD® Test is certified with the CE Mark under the In Vitro Diagnostic Regulation (IVDR, EU 2017/746), ensuring that the test complies with the European Union’s strict safety and performance standards. In addition to the development and commercialization of the MAP-AD®, the company continues to work on incorporating new solutions in the field of neurodegenerative diseases to improve the quality of life for patients and their families.
Innovation
Our team has an innovative vision that has allowed us to develop a disruptive approach to the market.
Efficiency and Effectiveness
We optimize our resources to achieve each of our scientific and business objectives.
Agility
We adopt agile and solid decisions to achieve our goals within the agreed timeframe.
A crucial step towards personalized medicine
The MAP-AD® test provides a prognosis for the progression from Mild Cognitive Impairment to Alzheimer’s Disease Dementia. This solution links disease biology, mitochondrial dysfunction, with cognitive changes. This is achieved through the analysis of novel blood biomarkers, mitochondrial DNA methylation, along with key disease risk factors (ApoE genotype and age), and neuropsychological assessment. Predicting cognitive decline years in advance opens the door to earlier interventions and optimizes patient selection for clinical trials, representing a significant advance in personalized and precision medicine.
Lastest news
- September 19, 2025
The MAP-AD® Test obtains the CE-IVDR mark, the first prognostic test for Alzheimer’s disease dementia
Barcelona – September 19, 2025 – ADmit Therapeutics S.L. announced today that its disruptive blood test for the prognosis of Alzheimer’s dementia, the MAP-AD® Test, has received the CE Mark under the In Vitro Diagnostic Regulation (IVDR, 2017/746). This certification confirms that the test complies with the European Union’s strict safety and performance standards, a significant milestone for […]
- September 19, 2025
ADmit Therapeutics publishes a key study on a new blood-based biomarker that predicts the progression to Alzheimer’s dementia
Barcelona – September 19, 2025– ADmit Therapeutics S.L. today announced the publication of a blood biomarker in the journal iScience (Cell Press). The study details the fundamental research that led to the development of the Test MAP-AD®, a prognostic solution based on mitochondrial DNA methylation levels in blood that predicts progression to Alzheimer’s dementia in patients with Mild Cognitive Impairment (MCI). […]
- July 27, 2025
ADmit Therapeutics is Attending the AAIC 2025 in Toronto
July 27, 2025. We are excited to announce that our company is attending the Alzheimer’s Association International Conference 2025 (AAIC25) in Toronto, Canada, from July 27 to July 31, 2025. The AAIC is the world’s largest and most influential meeting dedicated to advancing dementia science. Organized by the Alzheimer’s Association, this global forum brings together researchers, clinicians, and industry leaders to […]
Team
Members of the Board of Directors
Ferran
Prat
Chairman of the Board of Directors
Marta Barrachina
Co-Founder
CEO
Santiago Lozano
Board of
Directors
Maite
Fibla
Board of
Directors
This project has received funding from the European Union’s H2020 research and innovation program under number 960327.
